US 11,891,376 B2
Aryl cyclopropyl-amino-isoquinolinyl amide compounds
Mitchell A. deLong, Chapel Hill, NC (US); Jill M. Sturdivant, Chapel Hill, NC (US); Cynthia L. Lichorowic, Raleigh, NC (US); and Andriy Kornilov, Ypsilanti, MI (US)
Assigned to Aerie Pharmaceuticals, Inc., Bedminster, NJ (US)
Filed by Aerie Pharmaceuticals, Inc., Bedminster, NJ (US)
Filed on Aug. 25, 2022, as Appl. No. 17/895,436.
Application 17/895,436 is a division of application No. 16/570,849, filed on Sep. 13, 2019, granted, now 11,427,563.
Claims priority of provisional application 62/731,609, filed on Sep. 14, 2018.
Claims priority of provisional application 62/738,962, filed on Sep. 28, 2018.
Prior Publication US 2023/0227430 A1, Jul. 20, 2023
Int. Cl. C07D 401/14 (2006.01); C07D 417/12 (2006.01); C07D 401/12 (2006.01); A61P 27/06 (2006.01); C07D 413/12 (2006.01); C07D 405/12 (2006.01); C07D 417/14 (2006.01)
CPC C07D 401/14 (2013.01) [A61P 27/06 (2018.01); C07D 401/12 (2013.01); C07D 405/12 (2013.01); C07D 413/12 (2013.01); C07D 417/12 (2013.01); C07D 417/14 (2013.01)] 27 Claims
 
1. A method of treating an ocular disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof,
wherein
R1 is H, halo, —CN, —C1-6 alkyl, —C1-6 alkoxyl, —C1-6 haloalkyl, —C1-6 haloalkoxyl;
R2 is H or halo;
X is —(C1-5 heteroaryl)-R3; and
R3 is —C2-6 heterocyclyl, or —C1-6 heteroalkyl.